bluebird bio, Inc. (NASDAQ:BLUE) insider Jeffrey T. Walsh sold 4,900 shares of the business’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $125.73, for a total value of $616,077.00. Following the completion of the transaction, the insider now directly owns 32,205 shares of the company’s stock, valued at $4,049,134.65. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Shares of bluebird bio, Inc. (NASDAQ:BLUE) traded down 1.25% during mid-day trading on Wednesday, hitting $126.30. The stock had a trading volume of 711,278 shares. The firm’s market cap is $5.76 billion. bluebird bio, Inc. has a 52-week low of $37.05 and a 52-week high of $133.10. The firm has a 50 day moving average price of $103.57 and a 200 day moving average price of $95.55.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.66) by ($0.07). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The company had revenue of $16.70 million for the quarter, compared to analysts’ expectations of $6.29 million. During the same period in the prior year, the business earned ($1.59) EPS. The business’s quarterly revenue was up 977.4% compared to the same quarter last year. Equities analysts predict that bluebird bio, Inc. will post ($6.84) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/13/insider-selling-bluebird-bio-inc-blue-insider-sells-4900-shares-of-stock.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Hanseatic Management Services Inc. grew its holdings in shares of bluebird bio by 0.3% during the second quarter. Hanseatic Management Services Inc. now owns 10,436 shares of the biotechnology company’s stock worth $1,096,000 after buying an additional 27 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in shares of bluebird bio by 1.7% during the second quarter. Teacher Retirement System of Texas now owns 3,250 shares of the biotechnology company’s stock worth $341,000 after buying an additional 53 shares during the last quarter. Martingale Asset Management L P grew its holdings in shares of bluebird bio by 0.6% during the first quarter. Martingale Asset Management L P now owns 17,008 shares of the biotechnology company’s stock worth $1,547,000 after buying an additional 100 shares during the last quarter. Cornerstone Capital Management Holdings LLC. grew its holdings in shares of bluebird bio by 0.8% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 17,955 shares of the biotechnology company’s stock worth $1,885,000 after buying an additional 140 shares during the last quarter. Finally, Prudential Financial Inc. grew its holdings in shares of bluebird bio by 4.0% during the second quarter. Prudential Financial Inc. now owns 3,882 shares of the biotechnology company’s stock worth $408,000 after buying an additional 150 shares during the last quarter.

Several brokerages recently weighed in on BLUE. Zacks Investment Research downgraded bluebird bio from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Cantor Fitzgerald set a $37.00 target price on bluebird bio and gave the stock a “sell” rating in a research note on Monday, June 5th. Wedbush restated an “outperform” rating on shares of bluebird bio in a research note on Tuesday, June 6th. BTIG Research restated a “buy” rating and set a $112.00 target price on shares of bluebird bio in a research note on Thursday, June 1st. Finally, Morgan Stanley boosted their target price on bluebird bio from $103.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Monday, August 7th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the company. bluebird bio presently has a consensus rating of “Hold” and a consensus price target of $107.86.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Stock Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related stocks with our FREE daily email newsletter.